NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

MESOBLAST LIMITED (MSB)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of MSB: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Link Market Services Melbourne
Tower 4, 727 Collins Street Docklands VIC 3008
Tel : +61 3 9615 9800
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000MSB8
Address: Level 38 55 Collins Street Melbourne, VIC 3000 Australia
Tel:  (03) 9639 6036Fax: (03) 9639 6030

Date first listed: 16/12/2004
Company Secretary: Paul Hughes, Niva Sivakumar
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Australian biotechnology company committed to the development of treatments for orthopaedic conditions, including the commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage

News & Events

Expand this box to read and print

The suspension of trading in the securities of Mesoblast Limited will be lifted immediately following the release by MSB of an announcement regarding a private placement.

26/04/2023

The company releases a notice of proposed issue of securities.

26/04/2023

The company has completed a global private placement primarily to Mesoblast's existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share.

26/04/2023

The securities of Mesoblast Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MSB, pending the release of an announcement regarding a private placement.

24/04/2023

The suspension of trading in the securities of Mesoblast Limited will be lifted immediately following the release by MSB of an announcement regarding a capital raising.

09/08/2022

The company has completed a US$45 million (A$65 million) financing via the issue of 86.7 million fully-paid, ordinary shares in a global private placement led by its largest shareholder, M&G Investments, United Kingdom, and strongly supported by its major Australian and American shareholders. The private placement was made at A$0.75 per share, a 5% discount to the thirty trading-day volume weighted average price (VWAP), without any associated warrants or options. Inclusive of the US$45 million private placement, pro-forma cash-on-hand at June 30, 2022 is approximately US$105.5 million.

09/08/2022

The securities of Mesoblast Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of MSB, pending the release of an announcement regarding a capital raising.

08/08/2022

The securities of Mesoblast Limited (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company.

14/06/2016

The company provides an update on its global heart failure program.

14/06/2016

The company advises that the suspension of trading in its securities will remain in place pending an announcement regarding material corporate developments with respect to certain assets of the Company. The Company expects the voluntary suspension to remain in place until the earlier of the commencement of trading on 14 June 2016 and the Company making an announcement with respect to the corporate developments.

10/06/2016

The securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company.

03/06/2016

The securities of Mesoblast Limited (the "Company") will be reinstated to quotation immediately, following the release of an announcement by the Company. Security Code: MSB

16/11/2015

Mesoblast Limited (ASX:MSB; NASDAQ:MESO) today announced it had listed on the Nasdaq Global Market on 13 November under the symbol "˜MESO

16/11/2015

Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has filed a US registration statement on Form F-1 with the U.S. Securities and Exchange Commission, offering 5,742,510 American Depositary Shares (ADSs) in the United States, with each ADS representing five fully paid ordinary shares of Mesoblast (Shares). The actual number of ADSs and the issue price, in U.S. dollars, will be determined by Mesoblast in conjunction with the Company's underwriters at the conclusion of the offer process.

03/11/2015

Mesoblast Limited (ASX: MSB, USOTC: MBLTY) announced today that it plans to conduct a registered initial public offering in the United States. Mesoblast has previously submitted to the U.S. Securities and Exchange Commission (the "SEC") a draft registration statement. Mesoblast intends to publicly file its registration statement with the SEC and commence the offering next week.

30/10/2015

The company lodges its quarterly report.

30/10/2015

The securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company. Security Code: MSB

30/10/2015

shares reinstated to quotation

12/05/2010

the securities of Mesoblast Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company

05/05/2010

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    29/12/2023Joseph Swedish850$1.080
    USD
    $918
    28/12/2023Philip Krause37,500$1.108
    USD
    $41,536
    28/12/2023Joseph Swedish91,035$1.088
    USD
    $99,082
    21/12/2023Philip Facchina-30,000$1.080
    USD
    $32,400
    05/06/2023Philip Krause20,000$3.705
    USD
    $74,100

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Joseph SwedishNon Exec Chairman19/06/2018
    William BurnsVice Chairman06/03/2014
    Silviu ItescuManaging Director, CEO08/06/2004
    Dagmar Rosa-BjorkesonCOO24/07/2020
    Andrew ChaponnelCFO30/08/2021
    Philip KrauseDirector24/03/2022
    Jane BellDirector18/08/2022
    Eric RoseDirector17/04/2013
    Philip FacchinaDirector29/03/2021

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Michael SpoonerNon Exec Director15/08/200528/09/2023
    Shawn TomaselloNon Exec Director11/07/201818/08/2022
    Donal O'DwyerDeputy Chairman, Non Exec Director29/09/200427/02/2022
    Paul HodgkinsonCFO25/08/201430/08/2021
    Josh MuntnerCFO31/05/201830/08/2021
    Brian JamiesonNon Exec Chairman22/11/200731/03/2019
    Ben-Zion WeinerNon Exec Director10/05/201220/06/2018
    Jenni PilcherCFO01/11/200731/08/2014
    Kevin BuchiNon Exec Director30/12/201009/05/2012
    Byron McAllisterNon Exec Director29/09/200429/11/2010

    Date of first appointment, title may have changed.